Answers are grounded in this paper and cite their sources.
Glycogen storage disease type III (GSD III) is characterized by abnormally high glycogen accumulation in liver, muscle, and heart. Treatments such as diet modification and drugs are currently being developed, but there is a lack of suitable methods for assessing disease load and possible treatment efficacy. Recently, it was shown that glycoNOE MRI can image glycogen levels in vivo and here we apply this technique to distinguish GSD III from controls in a mouse model. The results show that glycoNOE can clearly distinguish GSD III and that glycoNOE contrast exhibits a linear correlation with ex vivo quantification of glycogen levels.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: